Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 5/20 | 0.46 |
| ▸ | EDNRB | P24530 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3188408 | 1.00 | EDNRA (0.46) | EDNRAEDNRBATMSERPINE1MEN1 | |
| SCHEMBL4781593 | 0.86 | ATM (0.37) | EDNRAATMSERPINE1MEN1KMT2A | |
| SCHEMBL4781594 | 0.86 | ATM (0.37) | EDNRAATMSERPINE1MEN1KMT2A | |
| SCHEMBL1656157 | 0.85 | EDNRA (0.43) | EDNRAEDNRBLMNAMAPK1HTT | |
| SCHEMBL1656158 | 0.85 | EDNRA (0.43) | EDNRAEDNRBLMNAMAPK1HTT | |
| SCHEMBL4625976 | 0.84 | ATM (0.36) | EDNRAATMSERPINE1MEN1KMT2A | |
| SCHEMBL1655803 | 0.83 | EDNRA (0.42) | EDNRAEDNRBHTT | |
| SCHEMBL1655802 | 0.83 | EDNRA (0.42) | EDNRAEDNRBHTT | |
| SCHEMBL4777117 | 0.78 | ATM (0.35) | EDNRAATMSERPINE1MEN1KMT2A | |
| SCHEMBL4777121 | 0.78 | ATM (0.35) | EDNRAATMSERPINE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | claimed |
| US-8420853-B2 | Derivatives of cyclic compound and the use thereof | Wonkisopharm Co., Ltd (KR) | 2013-04-16 | — | — | US | disclosed |
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | WONKISOPHARM CO., LTD. (KR) | 2010-01-28 | — | — | US | disclosed |
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | TYR, MC1R, PDE7A | EDNRA 1757/4885EDNRB 1354/4885ATM 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.